<?xml version="1.0" encoding="UTF-8"?>
<p id="Par12">Although, ZIKV strains have been phylogenetically characterized into African and Asian/American lineages, the virus has very little genome variability and is classified as a single serotype
 <sup>
  <xref ref-type="bibr" rid="CR67">67</xref>
 </sup>. This premise is supported by the report that primary infection with ZIKV African strain in macaques protected the animals from secondary heterologous re-challenge with ZIKV Asian strain
 <sup>
  <xref ref-type="bibr" rid="CR69">69</xref>
 </sup>. Thus, an effective ZIKV therapeutic candidate could potentially neutralize infection with any of the ZIKV virus lineages. Our 
 <italic>in vitro</italic> potency based on anti-ZIKV neutralization titer and 
 <italic>in vivo</italic> mouse results provide evidence that ZIKV-IG can effectively neutralize ZIKV infection.
</p>
